Xinping Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xinping Zhou has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Hongyan Tong
Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
11 shared publications Liya Ma
Department of Hematology The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou People's Republic of China
8 shared publicationsChen Mei
Department of Hematology The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou People's Republic of China
7 shared publications- Jie Jin
Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
7 shared publications Li Ye
Department of Hematology The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou People's Republic of China
7 shared publicationsLingxu Jiang
Department of Hematology the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China
6 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (5) , e71943
Finite‐Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia—A Pilot Study
Background: Continuous venetoclax‐azacitidine (VA) therapy is currently the major intervention for elderly or unfit acute myeloid leukemia (AML) patients. However, moderate chemotherapy with finite‐duration VA could achieve comparable or superior efficacy to infinite‐duration VA. Additionally, umbilical cord blood (UCB) transfusion improves clinical safety for elderly patients. Therefore, this single‐center study presents an improved approach: A finite‐duration VA and decitabine priming with intermediate‐dose cytarabine followed by UCB infusion. Methods: We included elderly AML patients who underwent the treatment between March 2021 and May 2024. Induction and maintenance regimens were VA. Our consolidation therapy involved intravenous decitabine (20 mg/m 2 d1–3), intermediate‐dose cytarabine (1.0 g/m 2 q12h d4–5), with subsequent UCB infusion (1.5% ± 25% × 10 7 /kg) d7. Our endpoints included duration of response (DOR), overall survival (OS), and safety. Results: We analyzed 16 patients with a median follow‐up of 53.6 months (95% CI: 36.2–71.0 months), and 7 out of 16 participants were at adverse risk. The median VA cycle number prior to disease relapse was 5 (IQR: 4–6). The median DOR was 17.4 months (95% CI: 7.3–27.5 months), with a 1‐year DOR rate of 68.8% and a 2‐year DOR rate of 35.2%. The median OS was 24.9 months (95% CI: 9.8–40.1 months), with a 1‐ and 2‐year OS rate of 100% and 55.6%. Specifically, among the 8 patients with IDH1/2 mutations, 4 experienced sustained remission, with 1‐year OS of 100%. Hematological and non‐hematological toxicities remained manageable during the consolidation phase. Conclusions: We demonstrated prolonged survival, particularly in patients with IDH mutations, using the modified intervention. This approach holds significant value for elderly patients with untreated AML who are unfit for standard treatments.
- 19 May 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (5) , e71943
Open AccessFinite‐Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia—A Pilot Study
Background: Continuous venetoclax‐azacitidine (VA) therapy is currently the major intervention for elderly or unfit acute myeloid leukemia (AML) patients. However, moderate chemotherapy with finite‐duration VA could achieve comparable or superior efficacy to infinite‐duration VA. Additionally, umbilical cord blood (UCB) transfusion improves clinical safety for elderly patients. Therefore, this single‐center study presents an improved approach: A finite‐duration VA and decitabine priming with intermediate‐dose cytarabine followed by UCB infusion. Methods: We included elderly AML patients who underwent the treatment between March 2021 and May 2024. Induction and maintenance regimens were VA. Our consolidation therapy involved intravenous decitabine (20 mg/m 2 d1–3), intermediate‐dose cytarabine (1.0 g/m 2 q12h d4–5), with subsequent UCB infusion (1.5% ± 25% × 10 7 /kg) d7. Our endpoints included duration of response (DOR), overall survival (OS), and safety. Results: We analyzed 16 patients with a median follow‐up of 53.6 months (95% CI: 36.2–71.0 months), and 7 out of 16 participants were at adverse risk. The median VA cycle number prior to disease relapse was 5 (IQR: 4–6). The median DOR was 17.4 months (95% CI: 7.3–27.5 months), with a 1‐year DOR rate of 68.8% and a 2‐year DOR rate of 35.2%. The median OS was 24.9 months (95% CI: 9.8–40.1 months), with a 1‐ and 2‐year OS rate of 100% and 55.6%. Specifically, among the 8 patients with IDH1/2 mutations, 4 experienced sustained remission, with 1‐year OS of 100%. Hematological and non‐hematological toxicities remained manageable during the consolidation phase. Conclusions: We demonstrated prolonged survival, particularly in patients with IDH mutations, using the modified intervention. This approach holds significant value for elderly patients with untreated AML who are unfit for standard treatments.
- 3 February 2025
- Published by Wiley in Hematological Oncology
- Vol. 43 (2) , e70043
Moderate‐To‐Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts
This study, including 412 patients newly diagnosed with myelodysplastic neoplasm (MDS), investigated the clinical, molecular, and prognostic features of MDS with moderate‐to‐severe bone marrow fibrosis (MF). Among the patients with MDS, 347 (84%) had MF grade 0–1 (MF0–1), and 65 (16%) had MF grade 2–3 (MF2–3). Patients with MDS with MF2–3 showed similar overall survival (OS) (16.6 vs. 21.3 months; p = 0.34) but demonstrated inferior progression‐free survival (PFS) (6.6 vs. 15.2 months; p = 0.02) and a higher risk of leukemia transformation (35.4 vs. 16.4%; p < 0.001) compared to those with MF0–1. In the MDS with excess blast (MDS‐EB) subtypes, individuals with MF2‐3 exhibited shorter OS (4.8 vs. 11.7 months; p = 0.01) and PFS (3.1 vs. 7.9 months; p = 0.006) than those in patients with MF0‐1. However, individuals with MF0‐1 and MF2‐3 showed similar OS and PFS rates among the patients with the MDS non‐excess blast (MDS‐nonEB) subtypes. Additionally, we reclassified the patients with MDS according to the 2022 World Health Organization (WHO) classification. Patients with MDS with fibrosis (MDS‐f) had a shorter OS (5.6 vs. 13.8 months; p = 0.01) and PFS (3.1 vs. 7.9 months; p = 0.006) than MDS with increased blasts (MDS‐IB) subtypes. Our study reveals the unique features of patients with MDS‐MF2‐3 and validates the refinements made in the 5th edition of the WHO proposal.
- 3 February 2025
- Published by Wiley in Hematological Oncology
- Vol. 43 (2) , e70043
Moderate‐To‐Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts
This study, including 412 patients newly diagnosed with myelodysplastic neoplasm (MDS), investigated the clinical, molecular, and prognostic features of MDS with moderate‐to‐severe bone marrow fibrosis (MF). Among the patients with MDS, 347 (84%) had MF grade 0–1 (MF0–1), and 65 (16%) had MF grade 2–3 (MF2–3). Patients with MDS with MF2–3 showed similar overall survival (OS) (16.6 vs. 21.3 months; p = 0.34) but demonstrated inferior progression‐free survival (PFS) (6.6 vs. 15.2 months; p = 0.02) and a higher risk of leukemia transformation (35.4 vs. 16.4%; p < 0.001) compared to those with MF0–1. In the MDS with excess blast (MDS‐EB) subtypes, individuals with MF2‐3 exhibited shorter OS (4.8 vs. 11.7 months; p = 0.01) and PFS (3.1 vs. 7.9 months; p = 0.006) than those in patients with MF0‐1. However, individuals with MF0‐1 and MF2‐3 showed similar OS and PFS rates among the patients with the MDS non‐excess blast (MDS‐nonEB) subtypes. Additionally, we reclassified the patients with MDS according to the 2022 World Health Organization (WHO) classification. Patients with MDS with fibrosis (MDS‐f) had a shorter OS (5.6 vs. 13.8 months; p = 0.01) and PFS (3.1 vs. 7.9 months; p = 0.006) than MDS with increased blasts (MDS‐IB) subtypes. Our study reveals the unique features of patients with MDS‐MF2‐3 and validates the refinements made in the 5th edition of the WHO proposal.
- Open Access
- 19 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (16) , eadi1782
RIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells
Mutant isocitrate dehydrogenases (IDHs) produce R-2-hydroxyglutarate (R-2HG), which inhibits the growth of most acute myeloid leukemia (AML) cells. Here, we showed that necroptosis, a form of programmed cell death, contributed to the antileukemia activity of R-2HG. Mechanistically, R-2HG competitively inhibited the activity of lysine demethylase 2B (KDM2B), an α-ketoglutarate–dependent dioxygenase. KDM2B inhibition increased histone 3 lysine 4 trimethylation levels and promoted the expression of receptor-interacting protein kinase 1 (RIPK1), which consequently caused necroptosis in AML cells. The expression of RIPK3 was silenced because of DNA methylation in IDH-mutant (mIDH) AML cells, resulting in R-2HG resistance. Decitabine up-regulated RIPK3 expression and repaired endogenous R-2HG–induced necroptosis pathway in mIDH AML cells. Together, R-2HG induced RIPK1-dependent necroptosis via KDM2B inhibition in AML cells. The loss of RIPK3 protected mIDH AML cells from necroptosis. Restoring RIPK3 expression to exert R-2HG’s intrinsic antileukemia effect will be a potential therapeutic strategy in patients with AML.
- 19 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (16) , eadi1782
Open AccessRIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells
Mutant isocitrate dehydrogenases (IDHs) produce R-2-hydroxyglutarate (R-2HG), which inhibits the growth of most acute myeloid leukemia (AML) cells. Here, we showed that necroptosis, a form of programmed cell death, contributed to the antileukemia activity of R-2HG. Mechanistically, R-2HG competitively inhibited the activity of lysine demethylase 2B (KDM2B), an α-ketoglutarate–dependent dioxygenase. KDM2B inhibition increased histone 3 lysine 4 trimethylation levels and promoted the expression of receptor-interacting protein kinase 1 (RIPK1), which consequently caused necroptosis in AML cells. The expression of RIPK3 was silenced because of DNA methylation in IDH-mutant (mIDH) AML cells, resulting in R-2HG resistance. Decitabine up-regulated RIPK3 expression and repaired endogenous R-2HG–induced necroptosis pathway in mIDH AML cells. Together, R-2HG induced RIPK1-dependent necroptosis via KDM2B inhibition in AML cells. The loss of RIPK3 protected mIDH AML cells from necroptosis. Restoring RIPK3 expression to exert R-2HG’s intrinsic antileukemia effect will be a potential therapeutic strategy in patients with AML.
- Open Access
- 21 November 2023
- Published by Wiley in American Journal of Hematology
- Vol. 99 (2) , E51-E54
Mutation landscape of normal karyotype myelodysplastic syndromes and their prognostic impact
- 21 November 2023
- Published by Wiley in American Journal of Hematology
- Vol. 99 (2) , E51-E54
Open AccessMutation landscape of normal karyotype myelodysplastic syndromes and their prognostic impact
- Open Access
- 25 July 2023
- Published by Wiley in Clinical and Translational Medicine
- Vol. 13 (7) , e1349
Serial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemia
- 25 July 2023
- Published by Wiley in Clinical and Translational Medicine
- Vol. 13 (7) , e1349
Open AccessSerial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemia
- 18 January 2023
- Published by Wiley in Hematological Oncology
- Vol. 41 (3) , 546-554
15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center study
The treatment of patients with refractory and/or relapsed (R/R) high‐risk myelodysplastic syndrome (HR‐MDS) remains a daunting clinical challenge. Venetoclax is a selective BCL‐2 inhibitor, which combined with hypomethylating agents (HMAs), increased responses and prolonged survival in unfit and previously untreated acute myeloid leukemia. We performed a retrospective study of patients with R/R HR‐MDS receiving combination azacytidine (AZA) plus 15‐days duration of venetoclax (VEN‐15d) in order to determine their efficacy and toxicity in this context. We showed that the overall response rate was 57.2% (20/35) and the median over survival was 14 months in R/R MDS. The most common treatment‐emergent adverse events were peripheral blood cytopenias and infectious complications. Our retrospective study showed that the real‐world experience of treating R/R MDS with AZA plus VEN‐15d highlights an encouraging response rate with myelosuppression being the major toxicity. Of note, VEN‐15d with AZA may salvage patients failing to respond optimally to HMAs and reduce the disease‐burden for subsequent allogeneic stem cell transplantation in our analysis. These data of combination AZA plus VEN‐15d in R/R MDS warrant further prospective evaluation in clinical trials.
- 18 January 2023
- Published by Wiley in Hematological Oncology
- Vol. 41 (3) , 546-554
15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center study
The treatment of patients with refractory and/or relapsed (R/R) high‐risk myelodysplastic syndrome (HR‐MDS) remains a daunting clinical challenge. Venetoclax is a selective BCL‐2 inhibitor, which combined with hypomethylating agents (HMAs), increased responses and prolonged survival in unfit and previously untreated acute myeloid leukemia. We performed a retrospective study of patients with R/R HR‐MDS receiving combination azacytidine (AZA) plus 15‐days duration of venetoclax (VEN‐15d) in order to determine their efficacy and toxicity in this context. We showed that the overall response rate was 57.2% (20/35) and the median over survival was 14 months in R/R MDS. The most common treatment‐emergent adverse events were peripheral blood cytopenias and infectious complications. Our retrospective study showed that the real‐world experience of treating R/R MDS with AZA plus VEN‐15d highlights an encouraging response rate with myelosuppression being the major toxicity. Of note, VEN‐15d with AZA may salvage patients failing to respond optimally to HMAs and reduce the disease‐burden for subsequent allogeneic stem cell transplantation in our analysis. These data of combination AZA plus VEN‐15d in R/R MDS warrant further prospective evaluation in clinical trials.
- Open Access
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 12351-12352
15-Days Duration of Venetoclax Combined with Azacitidine in the Treatment of Relapsed/Refractory High-Risk Myelodysplastic Syndromes: A Retrospective Single-Center Study
The treatment of patients with refractory and/or relapsed (R/R) high-risk myelodysplastic syndrome (HR-MDS) remains a daunting clinical challenge. Venetoclax is
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 12351-12352
Open Access15-Days Duration of Venetoclax Combined with Azacitidine in the Treatment of Relapsed/Refractory High-Risk Myelodysplastic Syndromes: A Retrospective Single-Center Study
The treatment of patients with refractory and/or relapsed (R/R) high-risk myelodysplastic syndrome (HR-MDS) remains a daunting clinical challenge. Venetoclax is
- Open Access
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 9767-9768
EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) is considered as an archetypal epigenetic disorder due to the aberrant epigenome, frequent epigenetic regulator mutations and th
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 9767-9768
Open AccessEZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) is considered as an archetypal epigenetic disorder due to the aberrant epigenome, frequent epigenetic regulator mutations and th
- Open Access
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 6894-6895
The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway
Background: RNA N6-methyladenosine (m6A) plays a critical role in normal and malignant hematopoiesis. The m6A methyltransferases METTL3 and METTL14 were reporte
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 6894-6895
Open AccessThe M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway
Background: RNA N6-methyladenosine (m6A) plays a critical role in normal and malignant hematopoiesis. The m6A methyltransferases METTL3 and METTL14 were reporte
- Open Access
- 20 February 2021
- Published by Wiley in Cancer Medicine
- Vol. 10 (5) , 1759-1771
Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes
Purpose: To explore the relevance of cytogenetic or molecular genetic abnormalities to clinical variables, including clinical and laboratory characteristics and prognosis in Chinese patients with myelodysplastic syndromes (MDS).Methods: A total of 634 consecutive patients diagnosed with MDS at The First Affiliated Hospital, Zhejiang University School of Medicine from June 2008 to May 2018 were retrospectively included in this study. All patients had evaluable cytogenetic analysis, and 425 patients had MDS‐related mutations sequencing.Results: 38.6% of patients displayed abnormal karyotypes. The most common cytogenetic abnormality was +8 (31%). Sole +8 was related to female (p = 0.002), hemoglobin >10 g/dL (p = 0.03), and p = 0.046). TP53 mutations were associated with complex karyotype (CK) (p < 0.001). DNMT3A mutations correlated with ‐Y (p = 0.01) whereas NRAS mutations correlated with 20q‐ (p = 0.04). The overall survival (OS) was significantly inferior in patients with +8 compared with those with normal karyotype (NK) (p = 0.003). However, the OS of sole +8 and +8 with one additional karyotypic abnormality was not different from NK (p = 0.16), but +8 with two or more abnormalities had a significantly shorter OS than +8 and +8 with one additional karyotypic abnormality (p = 0.02). In multivariable analysis, ≥60 years old, marrow blasts ≥5% and TP53 mutations were independent predictors for poor OS (p < 0.05), whereas SF3B1 mutations indicated better prognosis. Male IDH1 and IDH2 mutations and marrow blasts ≥5% were independent risk factors for worse leukemia free survival (LFS) (p < 0.05).Conclusion: In this population of Chinese patients, trisomy 8 is the most common karyotypic abnormality. Patients with +8 showed a poorer OS compared with patients with NK. Sole +8 and +8 with one additional karyotypic abnormality had similar OS with NK, whereas +8 with two or more abnormalities had a significantly shorter OS. DNMT3A mutations correlated with ‐Y and NRAS mutations correlated with 20q‐. TP53 mutations were associated with CK and had a poor OS. SF3B1 mutations indicated a favorable OS. IDH1 and IDH2 mutations independently indicated inferior LFS.
- 20 February 2021
- Published by Wiley in Cancer Medicine
- Vol. 10 (5) , 1759-1771
Open AccessClinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes
Purpose: To explore the relevance of cytogenetic or molecular genetic abnormalities to clinical variables, including clinical and laboratory characteristics and prognosis in Chinese patients with myelodysplastic syndromes (MDS).Methods: A total of 634 consecutive patients diagnosed with MDS at The First Affiliated Hospital, Zhejiang University School of Medicine from June 2008 to May 2018 were retrospectively included in this study. All patients had evaluable cytogenetic analysis, and 425 patients had MDS‐related mutations sequencing.Results: 38.6% of patients displayed abnormal karyotypes. The most common cytogenetic abnormality was +8 (31%). Sole +8 was related to female (p = 0.002), hemoglobin >10 g/dL (p = 0.03), and p = 0.046). TP53 mutations were associated with complex karyotype (CK) (p < 0.001). DNMT3A mutations correlated with ‐Y (p = 0.01) whereas NRAS mutations correlated with 20q‐ (p = 0.04). The overall survival (OS) was significantly inferior in patients with +8 compared with those with normal karyotype (NK) (p = 0.003). However, the OS of sole +8 and +8 with one additional karyotypic abnormality was not different from NK (p = 0.16), but +8 with two or more abnormalities had a significantly shorter OS than +8 and +8 with one additional karyotypic abnormality (p = 0.02). In multivariable analysis, ≥60 years old, marrow blasts ≥5% and TP53 mutations were independent predictors for poor OS (p < 0.05), whereas SF3B1 mutations indicated better prognosis. Male IDH1 and IDH2 mutations and marrow blasts ≥5% were independent risk factors for worse leukemia free survival (LFS) (p < 0.05).Conclusion: In this population of Chinese patients, trisomy 8 is the most common karyotypic abnormality. Patients with +8 showed a poorer OS compared with patients with NK. Sole +8 and +8 with one additional karyotypic abnormality had similar OS with NK, whereas +8 with two or more abnormalities had a significantly shorter OS. DNMT3A mutations correlated with ‐Y and NRAS mutations correlated with 20q‐. TP53 mutations were associated with CK and had a poor OS. SF3B1 mutations indicated a favorable OS. IDH1 and IDH2 mutations independently indicated inferior LFS.